FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:586-587 August 22, 1996 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Medications to treat benign prostatic hyperplasia fall into two main categories: ₁-adrenergic–antagonist drugs, which relax smooth muscle in the prostate, and drugs that inhibit 5-reductase, which shrink the prostate by blocking the formation of the chief intracellular androgen, dihydrotestosterone.¹ The main question is, Which drug is better, or would a combination of the two work best? In this issue of the Journal, Lepor et al. report the results of a landmark study by the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group that attempts to answer this question.²

The authors found that treatment with terazosin, an ₁-adrenergic antagonist, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Hoffman, R. M (2003). Review: terazosin improves urological symptoms in benign prostatic hyperplasia. Evid. Based Med. 8: 83-83 [Full Text]  
• Platz, E. A., Kawachi, I., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Willett, W. C., Giovannucci, E. (1998). Physical Activity and Benign Prostatic Hyperplasia. Arch Intern Med 158: 2349-2356 [Abstract] [Full Text]  
• Comaru-Schally, A. M., Brannan, W., Schally, A. V., Colcolough, M., Monga, M. (1998). Efficacy and Safety of Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix in the Treatment of Symptomatic Benign Prostatic Hyperplasia. J. Clin. Endocrinol. Metab. 83: 3826-3831 [Abstract] [Full Text]  
• Mendelsohn, R., Thompson, D., Collins, G. N, Taneja, S (1997). Drug treatment for benign prostatic hyperplasia. BMJ 315: 370-371 [Full Text]